OB
Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
$5.95 -6.30% (-$0.40)
1M +17.13%
Market Cap $380.2M
P/E Ratio -
Div. Yield -
ROE 125.93%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 12.92x
P/S 11.89x
P/FFO N/A
Growth
91 /100
Growing Book val. growth 6.45%
Rev. growth 111.62%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 181.36%
Gross margin 99.32%
FCF margin 184.83%
Quality
3 /100
Poor ROA 51.02%
ROIC 56.28%
Asset turnover 0.28x
Debt
54 /100
Moderate Int. coverage -27.37x
Debt/Equity 0.74x
Current ratio 8.26x
Stability
50 /100
Moderate EPS volatility 16.75%
Beta 0.53x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o OBIO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Hochman
Employees
86
Headquarters
New Hope
Prihajajoči dogodki
09 NOV.
Earnings
Upcoming earnings report